{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-040018","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.886914+00:00","generated_at":"2026-06-22T06:35:51.337573+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocuphire Q3 net loss $4.5M; Nyxol NDA on track for Q4 2022","bullets":["Cash and equivalents of $13.9M as of Sept 30, 2022; runway into Q4 2023.","Net loss of $4.5M for Q3 2022 ($0.22 per share); R&D expenses $2.8M.","NDA submission for Nyxol (reversal of mydriasis) planned in Q4 2022.","Topline data from ZETA-1 Phase 2b trial of APX3330 expected early 2023.","U.S. patent for Nyxol extended into 2039; new KOLs appointed to advisory board."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-040018","json":"https://secwatch.observer/filing/0001140361-22-040018.json","markdown":"https://secwatch.observer/filing/0001140361-22-040018.md","text":"https://secwatch.observer/filing/0001140361-22-040018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/0001140361-22-040018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/brhc10043741_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T06:35:51.337573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f66bca18257ffaaea6e2ce6fb8f9d5525f95040f","claim":"Opus Genetics, Inc. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 4, 2022, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/0001140361-22-040018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}